CN115536772B - Triglyceride molecularly imprinted polymer and preparation method and application thereof - Google Patents
Triglyceride molecularly imprinted polymer and preparation method and application thereof Download PDFInfo
- Publication number
- CN115536772B CN115536772B CN202211210175.6A CN202211210175A CN115536772B CN 115536772 B CN115536772 B CN 115536772B CN 202211210175 A CN202211210175 A CN 202211210175A CN 115536772 B CN115536772 B CN 115536772B
- Authority
- CN
- China
- Prior art keywords
- triglyceride
- molecularly imprinted
- imprinted polymer
- surface carrier
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229920000344 molecularly imprinted polymer Polymers 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000001603 reducing effect Effects 0.000 claims abstract description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 10
- 230000037396 body weight Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000178 monomer Substances 0.000 claims description 18
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 11
- 239000007810 chemical reaction solvent Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 5
- 238000000975 co-precipitation Methods 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 abstract description 22
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 22
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000295 complement effect Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000011246 composite particle Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 125000002133 (4-hydroxy-3-iodo-5-nitrophenyl)acetyl group Chemical group OC1=C(C=C(C=C1I)CC(=O)*)[N+](=O)[O-] 0.000 description 1
- -1 3, 5-diacetyl-1, 4-dihydrodimethylpyridine Chemical compound 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/04—Acids; Metal salts or ammonium salts thereof
- C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/268—Polymers created by use of a template, e.g. molecularly imprinted polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/10—Esters
- C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
- C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2335/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Derivatives of such polymers
- C08J2335/02—Characterised by the use of homopolymers or copolymers of esters
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
The first aspect of the invention provides a triglyceride molecularly imprinted polymer, which is prepared by taking triglyceride as a template molecule, and has a triglyceride recognition site for adsorbing the triglyceride, wherein the site is complementary with the triglyceride in the size, shape and function of a three-dimensional imprinting cavity, has good specificity, and can generate rapid and efficient specific adsorption on the triglyceride. Furthermore, the triglyceride molecularly imprinted polymer also comprises a surface carrier ferroferric oxide, so that the triglyceride molecularly imprinted polymer has good biocompatibility. In a second aspect, the invention provides a method for preparing a triglyceride molecularly imprinted polymer. In a third aspect the invention provides the use of a molecularly imprinted polymer of triglycerides for the preparation of a product for adsorbing or reducing triglyceride content, reducing hyperlipidemia or reducing body weight in a human.
Description
Technical Field
The invention belongs to the technical field of high molecular polymer materials, and particularly relates to a triglyceride molecularly imprinted polymer and a preparation method and application thereof.
Background
Blood lipids are a generic term for neutral fats (triglycerides) and lipids (phospholipids, glycolipids, sterols, steroids) in plasma, and are widely present in the human body, and they are essential substances for basic metabolism of living cells. In general, the main components in blood lipids are triglycerides and cholesterol, wherein Triglycerides (TG) are fatty molecules formed from long-chain fatty acids and glycerol, which are the most abundant lipids in the human body. Serum triglyceride is the total triglyceride in all lipoproteins, is clinically used as an important routine measurement index of blood fat, and is used as a basic item of blood fat measurement together with total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol. TG is mainly present in chylomicrons, very Low Density Lipoproteins (VLDL) and their remnant, which invade under vascular endothelium and the product of degradation by lipoprotein esterase (LPL) promotes foam cell production, leading to accelerated atherosclerosis. Atherosclerosis caused by hyperlipidemia is a major cause of coronary heart disease, hypertension and cerebrovascular disease, and about 1200 tens of thousands of people die of cardiovascular disease and cerebral stroke annually worldwide. Therefore, the prevention and treatment of hyperlipidemia is very important, which has attracted a great deal of attention from all humans.
Patients with critical high and high levels of triglycerides, often accompanied by complex hyperlipidemia and diabetic lipid disorders, are directly associated with coronary heart disease death and cardiovascular diseases (angina pectoris, myocardial infarction), and therefore lowering serum Triglyceride (TG) levels has become an indispensable aspect in the prevention and treatment of cardiovascular and cerebrovascular diseases. The current chemicals used for treating hyperlipidemia have quick and definite effects, but the chemicals have various degrees of toxic and side effects, such as common adverse reactions of atorvastatin, including digestive tract reactions, liver dysfunction and myalgia, which occur in patients who receive high doses and long-term treatment.
For the prevention and treatment of obesity related to hyperlipidemia, the weight-reducing drugs currently on the market are mainly two types, namely pancreatic lipase inhibitors and appetite suppressants acting on the central nervous system. The pancreatic lipase inhibitor orlistat has been reported to reduce weight by inhibiting pancreatic lipase activity and thus inhibiting the breakdown and absorption of fat in foods, but it causes steatorrhea, which can cause a deficiency of fat-soluble vitamins, and it has been reported recently that it can cause impairment of liver function. Appetite suppressants present safety risks in the brain central and cardiovascular systems, etc. due to adverse effects on the nervous system.
Disclosure of Invention
In view of the above problems, the first aspect of the present invention proposes a triglyceride molecularly imprinted polymer which is prepared with triglyceride as a template molecule and has a triglyceride recognition site to adsorb triglyceride.
According to the scheme, the triglyceride molecular imprinting polymer with the specific recognition cavity is prepared by taking the triglyceride as the template, so that a high-selectivity recognition site is obtained in the polymer structure, the site is complementary with the triglyceride in the size, shape and function of the three-dimensional imprinting cavity, the specificity is good, and the rapid and efficient specific adsorption can be generated on the triglyceride.
Preferably, the triglyceride molecularly imprinted polymer further comprises a functional monomer methacrylic acid.
Preferably, the triglyceride molecularly imprinted polymer further comprises a surface carrier of ferroferric oxide, fe 3 O 4 The magnetic nano particles have small size effect, good targeting property, biocompatibility and superparamagnetism, so that the triglyceride molecularly imprinted polymer prepared by taking magnetic ferroferric oxide as a surface carrier has good biocompatibility, can form more adsorption sites, and has high adsorption efficiency.
The second aspect of the invention provides a preparation method of a triglyceride molecularly imprinted polymer, which comprises the following steps:
s1, dissolving template molecule triglyceride in a reaction solvent, and adding a functional monomer for prepolymerization to obtain a solution A;
s2, adding a surface carrier and a functional reagent into the solution A, and obtaining a product B after reaction;
s3, eluting and drying the template molecules in the product B to obtain the product triglyceride molecularly imprinted polymer.
Further, the surface carrier is ferroferric oxide, and S2 further comprises the steps of coating the surface carrier with silicon dioxide and modifying amino groups. The silicon dioxide coating ensures that the magnetic composite particles have high stability, oxidation resistance and biocompatibility, the amino modification can improve the hydrophobicity of the magnetic composite particles, and the synthesis of the triglyceride molecularly imprinted polymer on the surface of the magnetic composite particles is facilitated.
Further, the preparation of the surface carrier comprises the following steps:
s21, synthesizing Fe by chemical coprecipitation method 3 O 4 ；
S22，Synthesis of Fe by Stober method 3 O 4 @SiO 2 ；
S23, the Fe 3 O 4 @SiO 2 And reacting with ethanol and 3-aminopropyl trimethoxy silane to obtain the product magnetic surface carrier.
Preferably, chloroform is used as the reaction solvent in S1. The triglyceride molecularly imprinted polymer prepared by using chloroform as a reaction solvent has a better adsorption effect on triglyceride.
Preferably, the functional monomer in S1 is methacrylic acid (MAA), the mole ratio of the template molecule triglyceride to the functional monomer methacrylic acid is 1:6, and the triglyceride molecularly imprinted polymer prepared by the mole ratio has a better adsorption effect on the triglyceride.
Preferably, the method comprises the steps of,
s1, dissolving template molecule triglyceride in chloroform, adding functional monomers, and performing prepolymerization at low temperature after ultrasonic dispersion;
s2, adding surface carrier magnetic ferroferric oxide, adding a cross-linking agent, an initiator and a pore-forming agent after ultrasonic dispersion, and reacting in a high-temperature anaerobic environment;
s3, eluting by using ethanol as an eluent until no triglyceride is detected in the reaction system.
In a third aspect, the invention provides the use of a triglyceride molecularly imprinted polymer prepared by any one of the above or any one of the above methods for the preparation of a product for adsorbing or reducing triglyceride content, reducing hyperlipidemia or reducing body weight in a human.
The invention selects triglyceride as a template, and prepares the molecularly imprinted polymer material capable of capturing triglyceride in human plasma by an atom transfer radical polymerization mode. The material can form a triglyceride-molecularly imprinted polymer complex and be discharged from the body, so that the molecularly imprinted material can be applied to products related to reducing the weight and the hypertriglyceridemia. Compared with the existing hypolipidemic drugs, the triglyceride molecularly imprinted polymer material prepared by the invention has the adsorption effect of high selectivity and strong specificity, and can realize the high-efficiency and rapid reduction of in-vivo triglyceride.
Drawings
The accompanying drawings assist in a further understanding of the present application. For convenience of description, only parts related to the related invention are shown in the drawings.
FIG. 1 is a flow chart of the preparation of a triglyceride molecularly imprinted polymer according to an embodiment;
FIG. 2 shows an embodiment of Fe 3 O 4 @SiO 2 -NH 2 Schematic of the preparation process of magnetic triglyceride molecularly imprinted polymer MIPs as a surface carrier;
FIG. 3 is an analysis of adsorption effect of triglyceride molecularly imprinted polymer on triglycerides of different concentrations according to an embodiment;
FIG. 4 is an illustration of the evaluation of biocompatibility and adsorption capacity of magnetic triglyceride molecularly imprinted polymers according to one embodiment;
FIG. 5 is a morphology characterization of a magnetic triglyceride molecularly imprinted polymer in one embodiment.
Detailed Description
The present application is described in further detail below with reference to the drawings and examples. The specific embodiments described herein are offered by way of illustration only, and not by way of limitation. Embodiments and features of embodiments in this application may be combined with each other without conflict.
FIG. 1 is a flow chart of the preparation of an embodiment of a triglyceride molecularly imprinted polymer, comprising the steps of:
s1, dissolving template molecule triglyceride in a reaction solvent, and adding a functional monomer for prepolymerization to obtain a solution A;
s2, adding a surface carrier and a functional reagent into the solution A, and obtaining a product B after reaction;
s3, eluting and drying the template molecules in the product B to obtain the product triglyceride molecularly imprinted polymer.
The Molecular Imprinting Technique (MIT) is a process of preparing a polymer having a specific selectivity for a specific molecule using the specific molecule as a template, i.e., preparing Molecularly Imprinted Polymers (MIPs) of the template molecule. According to the scheme, the MIPs are prepared by taking the triglyceride as the template molecule, so that the MIPs have high specific recognition and separation capability on the triglyceride, can be specifically extracted from a complex system, and have special selective recognition capability.
In a specific embodiment, the preparation of the triglyceride molecularly imprinted polymer comprises the steps of:
s1, dissolving 1mmol of template molecule triglyceride in 20mL of reaction solvent, adding functional monomer methacrylic acid, and prepolymerizing for 12h at 4 ℃ to obtain solution A;
s2, adding 0.2g of surface carrier into the solution A, performing ultrasonic dispersion for 15min, adding 20mmol of cross-linking agent EGDMA, 40mg of initiator AIBN, 40mL of pore-forming agent ACN, introducing nitrogen for 15min, and then placing in a 65 ℃ water bath for mechanical stirring for 24h to obtain a product B;
s3, using ethanol as an eluent, shaking the shaking table to remove the template until triglyceride cannot be detected in the eluent, obtaining the product MIPs, washing with water, and drying for later use.
In a specific embodiment, the detection of triglycerides is performed using a chemical assay, i.e., alkaline hydrolysis (saponification) of TG to oxidize glycerol with periodic acid to formaldehyde, followed by chromogenic reaction to determine formaldehyde. Chemical methods chemical assays typically include four stages: (1) extraction and separation of TG; (2) saponification; (3) oxidation of glycerol sugar; (4) oxidation to form formaldehyde for color development and quantification.
The reactions involved therein include:
TG+KOH→3RCH 2 COOK+ Glycerol
Glycerol +2HIO 4 →2HCHO+HCOOH
HCHO+2CH 3 COCH 2 COCH 3 +NH 4+ 3, 5-diacetyl-1, 4-dihydrodimethylpyridine
The preparation method of the reagent comprises the following steps:
saponification agent: weighing 6.0g KOH, dissolving in 60mL distilled water, adding 40mL isopropanol, mixing, placing in a brown bottle, and preserving at room temperature in a dark place;
oxidizing agent: 7.7g of anhydrous ammonium acetate is weighed and dissolved in a small amount of distilled water, 6mL of glacial acetic acid and 0.1g of periodic acid are added, distilled water is added to a volume of 100mL, and the mixture is placed in a brown bottle to be stored at room temperature and protected from light;
preparing a color-developing agent: taking 0.4mL of acetylacetone, adding isopropanol to 100mL, and placing in a brown bottle for storage at room temperature and in a dark place;
the measuring process comprises the following steps: taking 2 test tubes, adding 0.3mL of triglyceride standard solution and isopropanol solution respectively, adding 1mL of saponifier respectively, shaking completely and uniformly immediately, and heating in water bath at 65deg.C for 5min. And sequentially adding 1mL of an oxidant and 1mL of a color developing agent into each tube, fully vibrating and uniformly mixing, heating in a water bath at 65 ℃ for 15min, taking out, cooling to room temperature, measuring the absorbance at the wavelength of 420nm, correcting the zero point by using a blank tube, and reading the absorbance of each tube.
In a specific example, different reaction solvents were selected to prepare molecularly imprinted polymer MIPs, and correspondingly non-molecularly imprinted polymer MIPs were prepared in the same method without adding template molecules, and adsorption results on triglycerides are shown in the following table, and MIPs prepared in the different reaction solvents all have adsorption effect on triglycerides, and chloroform is the optimal reaction solvent.
TABLE 1 adsorption effect of MIPs prepared in different reaction solvents on triglycerides
In specific examples, molecularly imprinted polymer MIPs were prepared with different ratios of template molecules and functional monomers. Preparing 200 mug/mL standard triglyceride solution, taking three 4mL standard solutions and respectively synthesizing molecularly imprinted polymers with functional monomers, wherein the molar ratio of template molecules to the functional monomers is 1:4, 1:6 and 1:8 respectively, preparing non-molecularly imprinted polymers NIPs by the corresponding same method without adding template molecules, and fully adsorbing at room temperature, wherein the adsorption results are shown in the following table. It can be seen that MIPs prepared with different ratios of template molecules and functional monomers all have adsorption on triglycerides, with a 1:6 ratio being optimal.
TABLE 2 adsorption effects of MIPs prepared with different template molecules and functional monomers on Triglycerides
In a specific example, molecularly imprinted polymer MIPs were prepared with different nanomaterials as surface carriers, and correspondingly non-molecularly imprinted polymer MIPs were prepared in the same manner without the addition of template molecules, and the adsorption results of triglycerides thereof are shown in the following table. It can be seen that the polymers prepared with different surface carriers all have adsorption on triglycerides, and that of these, ferroferric oxide is the best carrier.
TABLE 3 adsorption effect of MIPs prepared with different surface Carriers on Triglycerides
In a further preferred embodiment, fe 3 O 4 @SiO 2 -NH 2 Magnetic triglyceride molecularly imprinted polymer MIPs with biosafety are prepared for the surface carrier. Fe with silica 3 O 4 The surface of the nano particle is coated to obtain the magnetic composite particle with high stability, oxidation resistance and biocompatibility, and then the amino modification is carried out on the magnetic composite particle to improve the hydrophobicity of the magnetic composite particle, and meanwhile, the synthesis of the triglyceride molecularly imprinted polymer on the surface of the magnetic composite particle is facilitated. FIG. 2 shows the composition of Fe in the present embodiment 3 O 4 @SiO 2 -NH 2 The preparation process of the magnetic triglyceride molecularly imprinted polymer MIPs serving as a surface carrier is schematically shown. Referring to fig. 2, the method specifically includes:
1. synthesis of Fe by chemical coprecipitation method 3 O 4 : weigh 3.44g FeCl 2 ·4H 2 O and 9.35g FeCl 3 ·6H 2 O, placing the mixture into a 250mL three-necked flask, adding 150mL of ultrapure water, slowly dropwise adding 20mL of ammonia water (25%, v/v) under rapid stirring, reacting for 1h in a nitrogen atmosphere at 90 ℃, separating solids by an external magnetic field, repeatedly washing precipitate with distilled water and absolute ethyl alcohol, washing the precipitate to be neutral by water, placing the precipitate into a vacuum drying oven, and drying at 75 ℃ for 12h to obtain magnetic Fe 3 O 4 A nanoparticle;
2. synthesis of Fe according to Stober method 3 O 4 @SiO 2 : 0.5g of Fe 3 O 4 Adding the powder into 60mL of mixed solution of ethanol and water (volume ratio of 5:1), performing ultrasonic treatment for 20min, pouring into a three-necked flask, stirring with a magnetic stirrer, slowly adding 2mL of ammonia water (25 wt%) and 2mL of tetraethyl orthosilicate (TEOS), stirring at 30deg.C for 6h, separating solid and solution with external magnet, soaking in 1mol/L hydrochloric acid solution for 24h, washing with water to neutrality, drying in a vacuum drying oven at 60deg.C for 12h, and collecting product Fe 3 O 4 @SiO 2 ；
3. Synthesis of Fe 3 O 4 @SiO 2 -NH 2 : 0.4g of Fe is weighed 3 O 4 @SiO 2 The powder was added with 90mL of ethanol and 5mL of 3-aminopropyl trimethoxysilane (APS), pH was adjusted to 4 with glacial acetic acid and stirred at 60℃for 4h; respectively cleaning with ethanol and hydrogen ion water for three times, and drying to collect solid;
4. preparation of MIPs-Fe 3 O 4 @SiO 2 : dissolving template molecule triglyceride 1mmol in 20mL chloroform, adding functional monomer methacrylic acid MAA 6mmol, prepolymerizing at 4deg.C for 12 hr, adding 0.2g prepared Fe 3 O 4 @SiO 2 -NH 2 Dispersing for 15min by ultrasonic, adding 20mmol of cross-linking agent EGDMA, 40mg of initiator AIBN, 40mL of pore-forming agent ACN, and introducing nitrogen for 15min. Placing the solution in a water bath at 65 ℃ for mechanical stirring for 24 hours, after the reaction is finished, using ethanol as an eluent, shaking a shaking table to remove the template until triglyceride cannot be detected in the eluent, washing the MIPs with water, and drying for later use.
Fig. 3 shows the adsorption effect of the molecularly imprinted polymer of triglyceride prepared in one embodiment on triglycerides with different concentrations, and it can be seen that the polymer prepared in the invention can effectively adsorb triglyceride in plasma, and the adsorption effect is better as the concentration of triglyceride increases.
Fig. 4 is an evaluation of biocompatibility and adsorption capacity of the magnetic triglyceride molecularly imprinted polymer prepared in one example. 3 healthy mice of the same age were taken, administered for 30 consecutive days (0.2 mg triglyceride molecularly imprinted polymer/g body weight), and weighed, and their body weight changes were observed. At the same time, 3 healthy mice of the same week-old were taken, administered for 30 consecutive days (0.2 mg cholestyramine/g body weight), and weighed to observe the change in body weight. Referring to fig. 4, after 30 days of continuous administration, mice survived, had good living status and slightly reduced body weight, and it can be seen that the triglyceride magnetic molecularly imprinted polymer prepared in this example has biological safety and the same, even better, body weight reducing effect as the hypolipidemic drug cholestyramine.
FIG. 5 is a morphological characterization of a magnetic molecularly imprinted polymer prepared in an example. The morphological characterization of the triglyceride magnetic molecularly imprinted polymer by a scanning electron microscope shows that the polymer has uniform shape and size, the particle diameter is about 100nm, and the surface is porous and uneven, namely, more imprinting sites are formed on the surface of the magnetic material.
The invention takes the triglyceride molecularly imprinted polymer as the adsorbent, and the cavity with specific size and functional group in the adsorbent is taken as the binding site of the triglyceride, so that the triglyceride in blood can be rapidly adsorbed and then discharged out of the body. The triglyceride magnetic molecularly imprinted polymer has strong selectivity, good adsorption effect and small side effect, can be used as a pharmaceutical composition for preventing and treating diseases related to hyperlipidemia, such as obesity, arteriosclerosis, hyperlipidemia, coronary heart disease, diabetes and other cardiovascular diseases; can also be used in weight-reducing medicines or health products, etc., to help reduce weight.
While the present application has been particularly shown and described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the application as defined by the appended claims.
Claims (5)
1. A triglyceride molecularly imprinted polymer, characterized in that the triglyceride molecularly imprinted polymer is prepared by taking triglyceride as a template molecule and has triglyceride recognition sites to adsorb the triglyceride, and further comprises a functional monomer methacrylic acid, wherein the mole ratio of the template molecule triglyceride to the functional monomer methacrylic acid is 1:6; the triglyceride molecularly imprinted polymer also comprises a surface carrier, and the preparation method of the surface carrier comprises the following steps:
s1, synthesizing Fe by a chemical coprecipitation method 3 O 4 ；
S2, synthesizing Fe by Stober method 3 O 4 @SiO 2 ；
S3, the Fe is 3 O 4 @SiO 2 And reacting with ethanol and 3-aminopropyl trimethoxy silane to obtain the product magnetic surface carrier.
2. A method for preparing a triglyceride molecularly imprinted polymer, which is characterized by comprising the following steps:
s21, dissolving template molecule triglyceride in a reaction solvent, and adding a functional monomer methacrylic acid for prepolymerization to obtain a solution A;
s22, adding a surface carrier, a cross-linking agent, an initiator and a pore-forming agent into the solution A, and obtaining a product B after reaction;
s23, eluting and drying the template molecules in the product B to obtain a product triglyceride molecularly imprinted polymer, wherein the mole ratio of the template molecule triglyceride to the functional monomer methacrylic acid is 1:6;
the preparation method of the surface carrier in the S22 comprises the following steps:
s31, synthesizing Fe by chemical coprecipitation method 3 O 4 ；
S32, synthesizing Fe by Stober method 3 O 4 @SiO 2 ；
S33, the Fe 3 O 4 @SiO 2 And reacting with ethanol and 3-aminopropyl trimethoxy silane to obtain the product magnetic surface carrier.
3. The method for preparing a triglyceride molecularly imprinted polymer according to claim 2, wherein the reaction solvent comprises chloroform.
4. The method for preparing the triglyceride molecularly imprinted polymer according to claim 2, wherein,
s21, specifically, dissolving template molecule triglyceride in chloroform, adding functional monomers, and performing prepolymerization at low temperature after ultrasonic dispersion;
s22, adding a surface carrier, adding a cross-linking agent, an initiator and a pore-forming agent after ultrasonic dispersion, and reacting in a high-temperature anaerobic environment;
s23 specifically comprises eluting with ethanol as eluent until no triglyceride is detected in the reaction system.
5. Use of a triglyceride molecularly imprinted polymer according to claim 1 or prepared according to the method of any one of claims 2-4 for the preparation of a product for adsorbing or reducing triglyceride content, reducing hyperlipidemia or reducing body weight in a human body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211210175.6A CN115536772B (en) | 2022-09-30 | 2022-09-30 | Triglyceride molecularly imprinted polymer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211210175.6A CN115536772B (en) | 2022-09-30 | 2022-09-30 | Triglyceride molecularly imprinted polymer and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115536772A CN115536772A (en) | 2022-12-30 |
| CN115536772B true CN115536772B (en) | 2023-12-22 |
Family
ID=84731842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211210175.6A Active CN115536772B (en) | 2022-09-30 | 2022-09-30 | Triglyceride molecularly imprinted polymer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115536772B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102417558A (en) * | 2011-11-21 | 2012-04-18 | 嘉兴学院 | Magnetic molecularly imprinted polymer for separating atrazine, and preparation method for magnetic molecularly imprinted polymer |
| JP2012224591A (en) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | Lipid absorption inhibitor |
| AU2020100965A4 (en) * | 2020-06-08 | 2020-08-20 | Animal Husbandry And Verterinary Research Institute Of Tibet Academy Of Agriculture And Animal Husbandry Sciences | Method For Preparation Of Solid Phase Extraction Column Of Sophocarpine Molecularly Imprinted Polymer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210835A1 (en) * | 2009-02-18 | 2010-08-19 | Board Of Regents, The University Of Texas System | Mimetic Drug Delivery Systems for Release with Specific Molecular Triggers |
-
2022
- 2022-09-30 CN CN202211210175.6A patent/CN115536772B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012224591A (en) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | Lipid absorption inhibitor |
| CN102417558A (en) * | 2011-11-21 | 2012-04-18 | 嘉兴学院 | Magnetic molecularly imprinted polymer for separating atrazine, and preparation method for magnetic molecularly imprinted polymer |
| AU2020100965A4 (en) * | 2020-06-08 | 2020-08-20 | Animal Husbandry And Verterinary Research Institute Of Tibet Academy Of Agriculture And Animal Husbandry Sciences | Method For Preparation Of Solid Phase Extraction Column Of Sophocarpine Molecularly Imprinted Polymer |
Non-Patent Citations (1)
| Title |
|---|
| Synthesis and application of magnetic surface molecularly imprinted polymers in selective solid-phase extraction of epoxy triglyceride from deep frying oil;Xinyu Cao et al.,;《Food Control》;第137卷;108896(1-8) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115536772A (en) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Preparation of bovine serum albumin surface-imprinted submicrometer particles with magnetic susceptibility through core− shell miniemulsion polymerization | |
| Bonitatibus Jr et al. | Preclinical assessment of a zwitterionic tantalum oxide nanoparticle X-ray contrast agent | |
| Yavuz et al. | Synthesis of cholesterol imprinted polymeric particles | |
| Li et al. | Preparation of imprinted polymers at surface of magnetic nanoparticles for the selective extraction of tadalafil from medicines | |
| Xu et al. | Fluorescent boronic acid polymer grafted on silica particles for affinity separation of saccharides | |
| CN103450361B (en) | Carboxymethyl cellulose grafted polylactic acid amphipathic nature polyalcohol and preparation method thereof and application | |
| Ciardelli et al. | Supported imprinted nanospheres for the selective recognition of cholesterol | |
| US20100291224A1 (en) | Nanostructures, methods of preparing and uses thereof | |
| Wilms et al. | Catechol-initiated polyethers: multifunctional hydrophilic ligands for PEGylation and functionalization of metal oxide nanoparticles | |
| CN109078614B (en) | Preparation method and application of branched boric acid-based glycoprotein molecular surface imprinted polymer | |
| CN108355625B (en) | Glycoprotein surface imprinted polymer based on boron affinity of team and preparation method and application thereof | |
| Hsiao et al. | Improved pH-responsive amphiphilic carboxymethyl-hexanoyl chitosan–poly (acrylic acid) macromolecules for biomedical applications | |
| JPH0665372A (en) | Polyaspartamide derivative | |
| Huang et al. | A facile FeBr3 based photoATRP for surface modification of mesoporous silica nanoparticles for controlled delivery cisplatin | |
| CN115536772B (en) | Triglyceride molecularly imprinted polymer and preparation method and application thereof | |
| Shi et al. | Microbubbles decorated with dendronized magnetic nanoparticles for biomedical imaging: effective stabilization via fluorous interactions | |
| Carrillo et al. | Biofunctionalized block copolymer nanoparticles based on ring‐opening metathesis polymerization | |
| CA2626823A1 (en) | Molecularly imprinted polymers , process for their preparation and their use to detect molecules in biological media | |
| Ji et al. | Maleimide Functionalized Poly (ε‐caprolactone)‐block‐poly (ethylene glycol)(PCL‐PEG‐MAL): Synthesis, Nanoparticle Formation, and Thiol Conjugation | |
| Xiao et al. | Novel controlled drug release system engineered with inclusion complexes based on carboxylic graphene | |
| CN106581647B (en) | PH-responsive insulin sustained-release nanoparticles and preparation method and application thereof | |
| CN109172517A (en) | A kind of preparation method of the microemulsion hydrogel as apiolin carrier with pH response | |
| TW588018B (en) | Method for preparation of water-soluble and dispersed iron oxide nanoparticles and application thereof | |
| TWI361082B (en) | Biocompatible polymer and magnetic nanoparticle with biocompatibilities | |
| CN113332964A (en) | Magnetic graft particles Fe3O4@SiO2Preparation method of (E) -PAM (polyacrylamide) and application thereof in amlodipine adsorption separation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |